GlassScriptPhysician profile
Heather M Weeks
NPI 1487217063
$5,922.44
in general payments reported to CMS, 2019-2025
39 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,567 · 2022: $1,280 · 2023: $840 · 2024: $1,207 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,075.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,068.36 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $863.03 | 2021-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $590.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $474.05 | 2021-2025 | Farxiga, Breztri, Nexium |
| E.R. Squibb & Sons, L.L.C. | $305.17 | 2021-2024 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $236.21 | 2021-2025 | Lifevest |
| Astellas Pharma US INC | $214.74 | 2021-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $196.60 | 2021-2025 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $188.49 | 2022-2025 | |
| Pfizer INC. | $175.99 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.80 | 2021-2025 | |
| Exact Sciences Corporation | $144.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Antares Pharma, INC. | $129.48 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Janssen Pharmaceuticals, INC | $127.28 | 2021 | |
| Amarin Pharma, INC. | $120.59 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $81.85 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.71 | 2021-2025 | Jardiance |
| Sun Pharmaceutical Industries INC. | $80.00 | 2022-2024 | |
| Abbott Laboratories | $72.35 | 2023-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.48 | 2024-2025 | Xifaxan |
| Dexcom, INC. | $60.22 | 2021-2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $58.79 | 2021-2024 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $54.59 | 2022-2025 | Uptravi |
| Incyte Corporation | $48.43 | 2021 | |
| Leo Pharma INC. | $42.33 | 2021 | |
| Verona Pharma, INC. | $39.68 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.17 | 2025 | Caplyta |
| Cvrx, INC. | $24.40 | 2025 | Barostim Neo System |
| Ucb, INC. | $23.93 | 2025 | Bimzelx |
| Halozyme INC | $22.74 | 2023 | |
| Glaxosmithkline, LLC. | $19.45 | 2024 | Trelegy Ellipta |
| Kerecis Limited | $19.41 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Biohaven Pharmaceutical Holding Company LTD. | $19.13 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.97 | 2023 | Arcalyst |
| Seqirus USA INC | $16.24 | 2024 | Flucelvax, Fluad |
| Idorsia Pharmaceuticals US INC | $14.52 | 2023 | Quviviq |
| Boston Scientific Corporation | $14.29 | 2024 | Varithena Administration Pack |
| Medtronic, INC. | $13.14 | 2023 | Closurefast |
| Kowa Pharmaceuticals America, INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.